IP Library › Granted Patent US 10,435,731
Granted Patent B2
US 10,435,731 · App. 14/903,673 · Granted Oct 8, 2019

Multiple proteases deficient filamentous fungal cells and methods of use thereof

Inventors: Christopher Landowski (Helsinki, FI); Anne Huuskonen (Helsinki, FI); Ann Westerholm-Parvinen (Kirkkonummi, FI); Markku Saloheimo (Helsinki, FI); Anne Kanerva (Helsinki, FI); Jukka Hiltunen (Helsinki, FI)
Assignee: Glykos Finland Oy
C12P21/00C12N9/1051C12N9/14C12N9/48C12N9/485C12N9/58C12N15/80C12P21/02C12Y204/01258C12Y303/02006C12Y304/00C12Y304/17021C12Y304/21C12Y304/21062C12Y304/21078C12Y304/23C12Y304/23018C12Y304/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,435,731
App. No.
14/903,673
Granted
Oct 8, 2019
Kind
B2
Abstract

The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.

Claims (16)

1. A Trichoderma reesei filamentous fungal cell comprising at least one endogenous protease having reduced or no protease activity, and a recombinant polynucleotide encoding a heterologous polypeptide, wherein the gene encoding endogenous amp2 protease of SEQ ID NO:775 comprises a mutation that reduces or eliminates the activity of the endogenous amp2 protease, and wherein the production level of the heterologous polypeptide is at least two-fold higher than the production level of the same polypeptide as produced in a corresponding parental filamentous fungal cell in which the gene encoding endogenous amp2 protease of SEQ ID NO:775 does not comprise a mutation that reduces or eliminates the activity of the endogenous amp2 protease.

2. The Trichoderma reesei filamentous fungal cell of claim 1 , wherein the cell further has reduced or no detectable protease activity in at least three or four proteases selected from the group consisting of pep1 of SEQ ID NO: 1, pep2 of SEQ ID NO: 182, pep3 of SEQ ID NO:17, pep4 of SEQ ID NO: 37, pep5 of SEQ ID NO: 58, pep8of SEQ ID NO: 507, pep 11 of SEQ ID NO: 522, pep12 of SEQ ID NO: 530, tsp1 of SEQ ID NO: 66, slp1 of SEQ ID NO: 82, slp2 of SEQ ID NO: 98, slp3 of SEQ ID NO: 166, slp7of SEQ ID NO: 231, gap1 of SEQ ID NO: 118, and gap2 of SEQ ID NO: 129.

3. The Trichoderma reesei filamentous fungal cell of claim 2 , wherein the total protease activity is reduced to 40% or less, or 6% or less, of the total protease activity of the corresponding parental filamentous fungal cell in which the proteases do not have the reduced activity.

4. The Trichoderma reesei filamentous fungal cell of claim 1 , wherein the heterologous polypeptide is a mammalian polypeptide selected from the group consisting of an antibody and its antigen-binding fragments, a growth factor, an interferon, a cytokine, and an interleukin.

5. The Trichoderma reesei filamentous fungal cell of claim 1 , wherein the fungal cell further comprises ALG3 having reduced activity.

6. The Trichoderma reesei filamentous fungal cell of claim 5 , wherein the gene encoding ALG3 comprises a mutation that reduces or eliminates the corresponding activity.

7. The Trichoderma reesei filamentous fungal cell of claim 1 , further comprising

a) an N-acetylglucosaminyltransferase I catalytic domain, and, optionally,

b) an N-acetylglucosaminyltransferase II catalytic domain.

8. A method of improving the stability of a heterologous polypeptide, comprising

a) providing the Trichoderma reesei filamentous fungal cell of claim 1 , and

b) culturing the cell such that the heterologous polypeptide is expressed, wherein the heterologous polypeptide exhibits increased stability compared to the heterologous polypeptide produced in a corresponding parental filamentous fungal cell in which the endogenous amp2 protease does not have reduced activity.

9. A method of making a heterologous polypeptide, comprising

a) providing the Trichoderma reesei filamentous fungal cell of claim 1 ;

b) culturing the cell such that the heterologous polypeptide is expressed; and,

c) purifying the heterologous polypeptide.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2021
From: NOVARTIS AG; GLYKOS FINLAND OY
To: GLYKOS FINLAND OY
Reel/Frame 056061/0610 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2019
From: LANDOWSKI, CHRISTOPHER; HUUSKONEN, ANN; WESTERHOLM-PARVINEN, ANN; KANERVA, ANNE; HILTUNEN, JUKKA; SALOHEIMO, MARRKU
To: GLYKOS FINLAND OY
Reel/Frame 048776/0759 →
Priority Claims (1)
EP 13176001 · Jul 10, 2013 · regional
Continuity (1)
Related Publication 20160237466A1 · Aug 18, 2016